NBC News

Endocyte to Present Final PRECEDENT Study Data on Targeted Therapeutic EC145 and Companion Imaging Diagnostic EC20 at ASCO Annual Meeting

WEST LAFAYETTE, Ind., May 19, 2011 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging ...
NBC News

Endocyte's EC145 Meets Primary Endpoint in Phase 2 Study, Demonstrating 85 Percent (2.3 month) Improvement in Median Progression-Free Survival for Treatment of Platinum ...

Get unlimited access to ad-free articles and exclusive content. - 260 Percent (4.0 Month) Increase in Median Progression-Free Survival in Folate Receptor Positive Patient Subgroup - Plan to File for ...
Business Wire

Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson’s Disease

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE) announced today topline results from PRECEDENT, a double-blind, placebo-controlled Phase 2 study of the investigational oral ...
Yahoo Finance

Neurodegenerative Disorder-Focused Sage Therapeutics Stock Falls On Disappointing Parkinson's Data

Wednesday, Sage Therapeutics Inc (NASDAQ:SAGE) announced topline results from the PRECEDENT Phase 2 study of dalzanemdor (SAGE-718) in people with mild cognitive impairment in Parkinson’s Disease. The ...